Neuroendocrine neoplasms by cancer site
Neuroendocrine neoplasms (NENs) are a histological based group of cancers, originating in neuroendocrine cells which are found throughout the body. Neuroendocrine cells receive signals from the nervous system and respond by making, storing, and secreting a variety of peptides and hormones to help control many of the body’s functions. NENs occur where neuroendocrine cells become malignant, they can occur anywhere in the body, in all types of organs as well as in soft tissues.
The following data visualisations provide cancer incidence, prevalence and survival statistics for NENs by cancer site. The all cancers combined group is included within the visualisations and provides the aggregate of NENs and NENs types across all cancer sites. Cancer data commentary number 11 provides an overview of neuroendocrine neoplasm rates in Australia. It discusses neuroendocrine neoplasm cancer incidence and survival by type and cancer site.
Neuroendocrine neoplasms by cancer site - incidence and prevalence
The below visualisation provides NENs by cancer site incidence and prevalence, by sex and age group. Help with terms, and information about the data, is available by placing the mouse pointer over the icons found near the top of the data visualisation.
Neuroendocrine neoplasm incidence and prevalence by cancer site data visualisation
![](https://viz.aihw.gov.au:443/t/Public/views/NEN_incidence_prevalence/Incidence_Prevalence.png?:embed=y&:showVizHome=no&:display_spinner=no&:host_url=https%3a%2f%2fviz.aihw.gov.au)
NENs incidence and prevalence by cancer site data are available as supplementary tables.
Neuroendocrine neoplasm survival by cancer site
The number of neuroendocrine neoplasm types by cancer site in the survival visualisation is less than incidence. Incidence data is provided if there is at least one case in the years reported while survival rates are provided if there is a survival rate for at least one of the reporting periods. Reliable survival rates require considerably more cases.
In addition to the 5-year reporting periods, a 15-year reporting period (2006–2020) has been created to increase the likelihood of at least a limited range of survival statistics being available for rarer cancers. This period provides only a limited understanding of survival. A limitation of this period is that the rates may be more predominantly derived from earlier years where survival may differ compared to more recent periods.
Neuroendocrine neoplasm survival by cancer site data visualisation
![](https://viz.aihw.gov.au:443/t/Public/views/NEN_survival/NEN_Survival.png?:embed=y&:showVizHome=no&:display_spinner=no&:host_url=https%3a%2f%2fviz.aihw.gov.au)
Neuroendocrine neoplasm survival by cancer site data are available as supplementary tables.